Clovis Oncology (CLVS) Misses Q3 EPS by 55c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Clovis Oncology (CLVS) Misses Q3 EPS by 55c

Clovis Oncology Announces Third Quarter 2015 Operating Results

November 5, 2015 4:05 PM EST

New Drug Application (NDA) for rociletinib for the treatment of advanced EGFR-mutant T790M+ non-small cell lung cancer (NSCLC) on file with U.S. FDA Marketing Authorization Application (MAA) for rociletinib on file in E.U.; action expected mid-2016 Raised $298 million in July equity offering Enrollment now complete in mutant BRCA population required for U.S. NDA submission for rucaparib in advanced ovarian cancer Rucaparib U.S. NDA submission planned Q2 2016 Erle Mast, Clovis Chief... More